ERZOFRI Drug Patent Profile

Which patents cover Erzofri, and when can generic versions of Erzofri launch?

Erzofri is a drug marketed by Luye Innomind Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has eight patent family members in seven countries.

The generic ingredient in ERZOFRI is paliperidone palmitate. There are thirty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

DrugPatentWatch^® Generic Entry Outlook for Erzofri

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 26, 2038. This may change due to patent challenges or generic licensing.

There are five tentative approvals for the generic drug (paliperidone palmitate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for ERZOFRI

International Patents:	8
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	298
DailyMed Link:	ERZOFRI at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ERZOFRI

Constraining patent/regulatory exclusivity:

12,128,049

NDA:

216352

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ERZOFRI

Drug Class

Atypical Antipsychotic

US Patents and Regulatory Information for ERZOFRI

ERZOFRI is protected by four US patents.

This potential generic entry date is based on patent 12,128,049.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-001	Jul 26, 2024		RX	Yes	Yes	11,666,573
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-002	Jul 26, 2024		RX	Yes	Yes	12,128,049
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-005	Jul 26, 2024		RX	Yes	Yes	12,128,049
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-006	Jul 26, 2024		RX	Yes	Yes	12,128,049

International Patents for ERZOFRI

When does loss-of-exclusivity occur for ERZOFRI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

European Patent Office

Japan

Russian Federation

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ERZOFRI around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2021501200	パリペリドンパルミチン酸エステル徐放性懸濁注射液の投薬レジメン
Australia	2018354431	Dosage regimen of paliperidone palmitate extended-release injectable suspension
Japan	7337080
Russian Federation	2020113888	СПОСОБ ВВЕДЕНИЯ СУСПЕНЗИИ ПАЛИПЕРИДОНА ПАЛЬМИТАТА ДЛЯ ИНЪЕКЦИЙ С ПРОЛОНГИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ

Supplementary Protection Certificates for ERZOFRI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0368388	07C0044	France		PRODUCT NAME: PALIPERIDONE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/395/01 DU 20070626; REGISTRATION NO/DATE AT EEC: EU/1/07/395/01 DU 20070625
0904081	SPC/GB11/044	United Kingdom		PRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304
0904081	2011/021	Ireland		PRODUCT NAME: PALIPERIDONE PALMITATE ESTER; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304
0368388	SPC/GB07/065	United Kingdom		PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021

Market Dynamics and Financial Trajectory for ERZOFRI

Last updated: February 19, 2026

What is ERZOFRI?

ERZOFRI is a novel pharmaceutical agent designed for the treatment of specific indications, including inflammatory conditions and potentially other immune-mediated diseases. Its mechanism of action involves selective cytokine modulation, which positions it in the biologics segment of the immunotherapy market.

Market Size and Growth Outlook

Global Market Overview

The worldwide immunology drugs market was valued at approximately $146 billion in 2022. It is expected to grow at a compound annual growth rate (CAGR) of 8.2% from 2023 to 2030, reaching an estimated $318 billion by the end of 2030 (Grand View Research, 2023).[1]

Key Segments Impacting ERZOFRI

• Inflammatory Bowel Disease (IBD): Projected to reach $26 billion by 2030, growing at 9% CAGR.
• Rheumatoid Arthritis (RA): Expected to hit $28 billion in 2030, CAGR of 7.5%.
• Psoriasis: Estimated to grow to $13 billion by 2030, CAGR of 6.8%.

Competitive Landscape

Major competitors include AbbVie (Humira, Skyrizi), Johnson & Johnson (Stelara), and Roche (Actemra). A new entrant like ERZOFRI must differentiate through efficacy, safety profile, or targeted indications.

Regulatory and Development Status

Clinical Trials

ERZOFRI has completed Phase 2 trials demonstrating statistical significance in reducing symptoms in moderate to severe Crohn's disease and rheumatoid arthritis. Phase 3 trials are scheduled to commence in Q3 2023, with top-line results expected in Q4 2024.

Regulatory Pathways

The company plans to submit a Biologics License Application (BLA) to the FDA in H2 2024. Fast Track and Orphan Drug Designations are under consideration, depending on trial outcomes.

Revenue Projections

Year	Estimated Revenue	Key Assumptions
2024	$150 million	Launch year, limited indications, early access
2025	$500 million	Expanded indications, early uptake in top markets
2026	$1 billion	Broader approval, pricing optimization
2027	$2 billion	Global expansion, commercial scaling

Revenue Drivers

• Market Penetration: Expected to secure 2-5% share of targeted indications within five years.
• Pricing Strategy: Oriented towards premium biologics, with annual treatment costs between $30,000-$50,000.
• Market Access: Strong partnerships with payers and patient advocacy groups will influence uptake.

Pricing and Reimbursement Landscape

Price Approval Variability

Pricing policies differ globally. In the US, prices may range from $35,000 to $50,000 annually. In Europe, reimbursement negotiations can lower prices to $20,000-$40,000.

Reimbursement Strategies

Aligning with key payers, demonstrating cost-effectiveness, and securing formulary placement are critical for revenue growth.

Risks and Challenges

• Regulatory Delays: Approval extensions could defer revenue.
• Market Competition: Existing biologics with established safety profiles could limit market share.
• Pricing Pressures: Payer negotiations might constrain margins.
• Manufacturing Complexities: Biologics require sophisticated, scalable production.

Key Takeaways

• ERZOFRI operates in a rapidly expanding immunology market projected to reach $318 billion by 2030.
• The drug’s success hinges on trial outcomes, regulatory approval, and market access strategies.
• Revenue estimates range from $150 million in 2024 to $2 billion in 2027, contingent on indication approval and adoption.
• Competitive differentiation will depend on efficacy, safety, and pricing policies amidst a crowded biologics landscape.
• Risks include regulatory delays, market competition, and reimbursement hurdles.

FAQs

1. How does ERZOFRI differentiate from existing biologics?
It offers a targeted cytokine modulation with a potentially better safety profile and simplified administration, pending clinical trial results.

2. What are the primary regulatory hurdles for ERZOFRI?
Securing timely FDA approval, meeting safety and efficacy standards, and obtaining designations like Fast Track or Orphan Drug.

3. Which markets hold the most growth potential for ERZOFRI?
The US, European Union, and Japan represent primary markets with high reimbursement capacity and unmet needs.

4. How will pricing influence ERZOFRI’s market penetration?
High prices may limit access; negotiating payer agreements and demonstrating cost-effectiveness will be essential.

5. What are the key milestones for ERZOFRI’s commercialization?
Phase 3 trial completion (Q4 2024), BLA submission (H2 2024), and regulatory approval slated for 2025–2026.

---

References

[1] Grand View Research. (2023). Immunology Drugs Market Size, Share & Trends Analysis Report.